Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this ...
A multicenter clinical trial comparing the Dexcom G7 and FreeStyle Libre 3 continuous glucose monitors found the Libre 3 more accurate across all glucose ranges. Libre 3 recorded a lower mean absolute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results